⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCYX News
SCYNEXIS, Inc.
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
GSK
SCYX
PFE
MRK
CDTX
AMPH
ASTX
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
globenewswire.com
SCYX
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
globenewswire.com
SCYX
Rifles Market Analysis and Growth Forecast 2026-2032: Key Global and Regional Trends and Opportunities
globenewswire.com
SWBI
RGR
VFC
SCYX
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
globenewswire.com
SCYX
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
globenewswire.com
SCYX
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
globenewswire.com
SCYX
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
SCYX
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
globenewswire.com
SCYX
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
globenewswire.com
SCYX